Bristol-Myers Squibb

Alternance - Assistant(e) Chef de produit Oncologie

Rueil-Malmaison, Ile-de-France, France

Not SpecifiedCompensation
Junior (1 to 2 years)Experience Level
Full TimeJob Type
UnknownVisa
Pharmaceuticals, HealthcareIndustries

Requirements

Candidates should possess a double scientific formation (doctor, pharmacist, scientist, veterinarian) plus a 3rd cycle in Marketing or a similar ESC type formation, demonstrating an interest in science and the healthcare sector, as well as an interest in accessing the market for pharmaceutical products. Strong computer skills and fluent English are also required.

Responsibilities

The Assistant Chef de Produit Mélanome will be responsible for the development and implementation of the communication strategy for an innovative product portfolio in Immuno-Oncology within a rapidly changing market. This includes managing and following up on operational projects in support of the marketing team, creating and validating promotional tools within regulatory and legal constraints, participating in the construction of educational programs, analyzing and following up on customer operations (RP programs, staff, congresses), involvement in the organization of sales force seminars, tracking the training of representatives, working closely with various stakeholders (externally and internally) to assist the marketing team on ongoing projects, conducting competitive monitoring, and contributing to communication and training efforts.

Skills

Marketing
Communication Strategy
Regulatory Constraints
Promotional Tools
Educational Programs
Customer Operations
Sales Force Seminars
Competitive Monitoring
Training
Stakeholder Management
English

Bristol-Myers Squibb

Develops and delivers biopharmaceutical medicines

About Bristol-Myers Squibb

Bristol Myers Squibb (BMS) develops and delivers medicines aimed at treating serious diseases, focusing on areas like cancer, autoimmune diseases, and heart conditions. The company conducts extensive research and development to create new drugs, which are sold after receiving regulatory approval. BMS also produces generic drugs, offering affordable alternatives that meet the same quality standards as their branded counterparts. What sets BMS apart from competitors is its dual focus on both innovative and generic medicines, enhancing access to healthcare. The company's goal is to improve patient outcomes while maintaining a commitment to sustainability and corporate responsibility.

Key Metrics

New York City, New YorkHeadquarters
1887Year Founded
$33,706.1MTotal Funding
IPOCompany Stage
Biotechnology, HealthcareIndustries
10,001+Employees

Benefits

Flexible Work Hours
Hybrid Work Options
Professional Development Budget

Risks

Increased competition in oncology from emerging biotech firms like ArsenalBio.
BMS's lawsuit over the 340B Drug Pricing Program may lead to regulatory challenges.
Rapid AI and digital tech evolution may pose integration challenges for BMS.

Differentiation

BMS focuses on innovative cancer treatments through collaborations like ArsenalBio for T cell therapies.
The company emphasizes digital health technologies, enhancing clinical trial management and patient engagement.
BMS offers both innovative and generic medicines, increasing affordable healthcare solutions.

Upsides

BMS's partnership with Medidata enhances clinical research processes and patient outcomes.
The collaboration with AI Proteins advances novel miniprotein-based therapeutics, expanding therapeutic modalities.
BMS's global license agreement with BioArctic expands its portfolio in neurodegenerative diseases.

Land your dream remote job 3x faster with AI